Tocilizumab, a kind of antibody that targeted the IL-6 signaling pathway, was demonstrated to be effective in treating severe COVID-19 patients, and biomarkers including C-reactive protein, procalcitonin, D-dimer, and lymphocyte levels were decreased after receiving tocilizumab administration [20, 92]. The gene discussed is CRP; the disease is COVID-19.